PHC Holdings Returns to Profit with ¥13.313 Billion in First Half
Key Facts
PHC Holdings said on November 11, 2026, that it returned to profit in the first half of its fiscal year ending in March 2027, posting net profit attributable to owners of the parent of ¥13.313 billion for the period from April 1 to September 30, 2026. The company recorded a loss of ¥559 million in the same period a year earlier. Revenue rose to ¥179.970 billion, up 3.8% year on year, while operating profit climbed to ¥19.439 billion, up 87.3%. The results show improved profitability alongside revenue growth, with performance varying across the company's segments. Diabetes management, diagnostics and life sciences provided support, while healthcare solutions revenue declined.
The diabetes management segment was one of the main sources of growth, with revenue rising 12.3% to ¥54.655 billion. The company attributed the performance to strong sales in Europe and improved demand in the Middle East, as well as progress in localization in Algeria and the impact of foreign exchange rates. The segment's operating profit rose 99.0% to ¥18.565 billion, approaching twice its level a year earlier. The company said cost reductions contributed to the improvement, while profitability also improved following the transfer of its continuous glucose monitoring business. The segment's performance thus combined sales growth with improved margins, in line with the operational factors cited by the company.
The diagnostics and life sciences segment posted revenue of ¥65.681 billion, up 6.0% from the same period. Its operating profit surged 153.5% to ¥4.292 billion. The company pointed to the impact of price revisions and higher consumables sales on the segment's growth. Lower selling, general and administrative expenses also helped operating profit rise faster than revenue. This reflects improvement in both sales and expenses in the first half, according to the company's explanation of the results.
By contrast, the disclosure showed a decline in healthcare solutions, making the improvement in results uneven across the businesses. This came alongside growth in diabetes management and diagnostics and life sciences, the two segments for which the disclosure reported positive first-half growth figures. The company did not provide a separate figure for healthcare solutions in its annual forecast in the data available here. Net profit attributable to owners of the parent remains the clearest measure of the overall turnaround, moving from a loss in the comparable period to a profit in the current period. The disclosure pairs this shift with increases in operating profit and revenue.
PHC Holdings maintained its forecast for the fiscal year ending in March 2027 at revenue of ¥366 billion, operating profit of ¥33 billion and profit attributable to owners of the parent of ¥18 billion. The company said its operating forecast had been revised, with no change to its dividend forecast. These figures place the first-half results in the context of the full fiscal year, with the published annual forecasts remaining at their stated levels. The interim results showed revenue and operating profit growth and a return to net profit. The announced forecast covers the fiscal year through March 31, 2027.